|
Health Condition(s) or Problem
|
Topic: Generic Health Relevance and Cross Cutting Themes; Subtopic: Generic Health Relevance (all Subtopics); Disease: Critical Care
|
|
Lay Summary
|
Sorry, not currently available
|
|
Who can enter the trial
|
1. Patients requiring mechanical ventilation within 72 hours of admission
2. Male and female, aged 18 - 99 years
|
|
Who cannot enter the trial
|
1. Allergy to haloperidol
2. Chronic antipsychotic use
3. QTc greater than 500 msecs
4. History of torsades de pointes
5. Family history of dystonic reactions
6. Moribund and not expected to survive
7. Uncomplicated elective surgery
8. Expected to stay less than 48 hours
9. Moderate/severe dementia
10. Pregnancy
11. Parkinsons disease
12. Structural brain damage
13. History of neuroleptic malignant syndrome
14. Patients who do not understand English
|
|
What will happen
|
Haloperidol 2.5 mg intravenously or 0.5 ml normal saline intravenously 8 hourly for up to 14 days or until the patient screens negative for delirium for 48 hours using the CAM-ICU.
Follow up length: 6 months
Study entry: single randomisation only
|
|
Primary aim
|
Delirium/coma free days, measured at 14 days
|
|
Secondary Aim
|
1. Incidence of delirium
2. Delirium/coma free days in first 28 days
3. Number of ventilator free days at 28 days
4. Length of critical care and hospital stay
5. Mortality and cause of death at 6 months
6. Organ failure free days
7. Cognitive decline
8. Health related quality of life
|
|
Participant Information Sheet
|
Not available in web format, please use the contact details below to request a patient information sheet
|
|
Website
|
Sorry, not currently available
|
|
Recruitment Status
|
Recruiting
|
|
Nation
|
England
|
|
Location
|
Watford
|